Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
169 hedge funds and large institutions have $1B invested in Array Biopharma Inc in 2016 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 46 increasing their positions, 40 reducing their positions, and 14 closing their positions.
300% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 14
125% more capital invested
Capital invested by funds: $445M → $1B (+$556M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
32% more funds holding
Funds holding: 128 → 169 (+41)
15% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 40
24% less call options, than puts
Call options by funds: $8.53M | Put options by funds: $11.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$16.8M |
| 3 |
Millennium Management
New York
|
+$14.1M |
| 4 |
O
OrbiMed
New York
|
+$12.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$7.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$26M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$9.64M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$6.96M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.87M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.33M |
ARRY Hedge Fund Activity: Q3 2016 in Review
169 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2016, worth a combined $1B — up 125% from $445M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ARRY positions and 14 closed out — a net gain of 42 holders — while 46 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.9M. The largest seller was Deerfield Management, cutting an estimated $26M.
- 169 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2016, up from 128 in Q2 2016.
- Funds reported $1B of Array Biopharma Inc stock for Q3 2016, up 125% quarter-over-quarter.
- 56 funds opened new Array Biopharma Inc positions in Q3 2016 and 14 closed out, a net change of +42 holders.
- The largest Array Biopharma Inc buyer in Q3 2016 was Fidelity Investments, an estimated $43.9M added.
- The largest Array Biopharma Inc seller in Q3 2016 was Deerfield Management, an estimated $26M sold.
Based on aggregated 13F filings for Q3 2016.